Description

Glucagon (19-29), human is a potent and efficient inhibitor of insulin secretion. –80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)–Neuroscience-Neuromodulation–C61H89N15O18S—-[1]Dalle S, et al. Miniglucagon (glucagon 19-29), a potent and efficient inhibitor of secretagogue-induced insulin release through a Ca2+ pathway. J Biol Chem. 1999 Apr 16;274(16):10869-76.|[2]Dalle S, et al. Miniglucagon (glucagon 19-29): a novel regulator of the pancreatic islet physiology. Diabetes. 2002 Feb;51(2):406-12.|[3]Pavoine C, et al. Miniglucagon [glucagon-(19-29)] is a component of the positive inotropic effect of glucagon. Am J Physiol. 1991 May;260(5 Pt 1):C993-9.–64790-15-4–1352.53–98.15–O=C(N[C@@H](CC(C)C)C(N[C@@H](CCSC)C(N[C@@H](CC(N)=O)C(N[C@H](C(O)=O)[C@H](O)C)=O)=O)=O)[C@@H](NC([C@H](CCC(N)=O)NC([C@H](C(C)C)NC([C@@H](NC([C@H](CC(O)=O)NC([C@H](CCC(N)=O)NC([C@@H](N)C)=O)=O)=O)CC1=CC=CC=C1)=O)=O)=O)CC2=CNC3=C2C=CC=C3–Neurological Disease–DMSO : ≥ 25 mg/mL–GCGR—-GPCR/G Protein–Peptides